Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Alzheimer's Medication Trials

North Carolina

Alzheimer's medication trials in North Carolina

12 Alzheimer's medication studies are recruiting participants at sites in 7 cities across North Carolina as of November 17, 2026, according to ClinicalTrials.gov.

Call (888) 927-5916
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every North Carolina city with a recruiting study

Matthews (5), Durham (3), Morehead City (3), Charlotte (2), Greensboro (1), Monroe (1), Raleigh (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Recently updated studies in North Carolina

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Recruiting in
    Matthews
    Registry record
    NCT05980949 · updated
  2. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Morehead City
    Registry record
    NCT06937229 · updated
  3. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Recruiting in
    Charlotte · Matthews
    Registry record
    NCT06540833 · updated
  4. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Morehead City
    Registry record
    NCT07011745 · updated
  5. A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

    • Phase 1
    • Ages 50 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Recruiting in
    Durham
    Registry record
    NCT06297590 · updated
  6. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    • Phase 3
    • Ages 55 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Recruiting in
    Monroe
    Registry record
    NCT07602582 · updated
  7. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Recruiting in
    Greensboro · Matthews · Morehead City
    Registry record
    NCT06585787 · updated
  8. A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

    • Phase 2
    • Ages 50 to 85
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Matthews
    Registry record
    NCT07033494 · updated
  9. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    Celgene
    Recruiting in
    Charlotte · Raleigh
    Registry record
    NCT06808984 · updated
  10. Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

    • Phase 2
    • Ages 50 and older
    • All sexes
    Sponsor
    Duke University
    Recruiting in
    Durham
    Registry record
    NCT06041789 · updated
  11. Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eidos Therapeutics, a BridgeBio company
    Recruiting in
    Durham
    Registry record
    NCT06563895 · updated
  12. Open-label Extension Study in Participants With Early Alzheimer's Disease

    • Phase 2
    • Ages 50 to 85
    • All sexes
    Sponsor
    GlaxoSmithKline
    Recruiting in
    Matthews
    Registry record
    NCT07105709 · updated

Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in North Carolina on ClinicalTrials.gov.

Ask about studies in North Carolina

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

Alzheimer's Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5916

or send a short form

How should we reach you?

Call